p53 Gene Alterations in Prostate Cancer After Radiation Failure and Their Association with Clinical Outcome: A Molecular and Immunohistochemical Analysis

Expression of p53 Protein and Tumor Angiogenesis as Prognostic Factors in Nasopharyngeal Carcinoma Patients

“…Wood et al [39], in SCC of the head and neck, reported that mutations of the p53 gene determined by PCR-SSCP were significantly associated with survival, but no significant association was observed when p53 expression was analyzed by IHC. In contrast, Rakozy et al [23] reported that p53 IHC study and not PCR-SCCP was associated with survival in prostate cancer. These results demonstrate that there is no perfect correlation between p53 gene mutations and the mutant protein expression.…”

“…This DO-7 antibody is highly recommended for retrospective studies on paraffin-embedded samples [9,23,31]. The DO-7 monoclonal antibody was diluted 1:100 and displayed by the streptavidin-biotin complex method [12].…”

Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study

“…34 The prognostic role of p53 protein accumulation has been well documented in a variety of tumors such as bladder, 35 colorectal, 36 and prostate cancer. 37 In contrast, immunohistochemical staining of p53 protein is infrequent in undifferentiated NPC. 29 Three retrospective series have failed to show a prognostic role of p53 protein expression in NPC.…”

TP53 Genotype but Not p53 Immunohistochemical Result Predicts Response to Preoperative Short-Term Radiotherapy in Rectal Cancer

“…17,18 Reviewing the analyses dealing with p53 immunohistochemical and treatment response, inconsistent results are reported, which might be attributed to various problems affecting this technique. 11,24,25 It has been shown that falsenegative immunohistochemical results can be explained by the presence of distinct mutations (e.g., deletions, insertions) that prevent transcription. However, the clinical value of positive immunohistochemistry in the absence of TP53 mutation remains unclear.…”